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Methods currently used for HIV-1 viral load measurements are very sensitive, but cannot distinguish between infectious and noninfectious
particles. Here we describe the development of a novel, sensitive, and highly reproducible method that allows rapid isolation and
quantification of infectious particles from patient plasma.
By immobilizing HIV-1 particles in human plasma to platelets using polybrene, we observed a 10- to 1000-fold increase in infectivity over
infection protocols using free virus particles. Using this method, we evaluated infectivity in plasma from 52 patients at various disease stages. At
plasma viral loads of 1000–10000HIV-1 RNA copies/ml 18%, at 10000–50000 copies/ml 73%, at 50000–100000 copies/ml 90%, and above
100000 copies 96% of cultures were positive.We found that infectious titers among patients vary distinctively but are characteristic for a patient
over extended time periods. Furthermore, we demonstrate that by evaluating infectious titers in conjunction with total HIV RNA loads, subtle
effects of treatment intervention on viremia levels can be detected. The immobilization procedure does not interfere with viral entry and does not
restore the infectivity of neutralized virus. Therefore, this assay system can be utilized to investigate the influence of substances that specifically
affect virion infectivity such as neutralizing antibodies, soluble CD4, or protease inhibitors. Measuring viral infectivity may thereby function as
an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV; Plasma viremia; Infectious titer; Virus isolationIntroduction
HIV-1 particles in plasma represent the most recently
produced quasispecies. Influences of the immune system or
therapies on viremia can most rapidly be monitored by
assessing this easily accessible compartment. Therefore, the
quantification and characterization of the plasma virus pool
is of particular interest for the diagnosis of HIV-1 infection
and assessment of disease progression. Current methods
routinely used for viral load measurements determine the
amount of genomic HIV-1 RNA copy numbers but cannot
distinguish between infectious and noninfectious or neu-
tralized particles in plasma (Coombs et al., 1993; Mellors et
al., 1997; Piatak et al., 1993b). Despite the high copy0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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of these particles has been described to be infectious
(Andreoni et al., 1997; Coombs et al., 1989; Escaich et
al., 1991; Ho et al., 1989; Lathey et al., 1994; Pan et al.,
1993; Piatak et al., 1993a, 1993b; The Division of AIDS,
National Institute of Allergy and Infectious Diseases and
National Institute of Health, 1997; Vella et al., 2000). Direct
co-culturing of patient plasma with donor cells is common-
ly used (Andreoni et al., 1997; Coombs et al., 1989;
Escaich et al., 1991; Ho et al., 1989; Lathey et al., 1994;
Pan et al., 1993; Piatak et al., 1993a; 1993b; The Division
of AIDS, National Institute of Allergy and Infectious
Diseases and National Institute of Health, 1997; Vella et
al., 2000) but has proven to be rather insensitive (Table 1).
Concentration of virus from patient plasma by centrifuga-
tion or precipitation before co-culturing the virus with
target cells has been shown to increase the in vitro
infectivity, but the necessary centrifugation and precipita-
tion steps are time consuming, laborious, and prone to
Table 1
Comparison of different virus isolation procedures
Reference Assay short description Number of successful virus isolations from plasma at different levels of HIV RNA copies/ml
< 10000 10000–100000 >100000
This work virus cross-linking to
platelets
1/12 (8.3%) 15/19 (78.9%) 20/21 (95.2%)
Piatak et al., 1993b direct plasma PBMC
co-culture
0/4 (0%) 2/21 (9.5%) 28/40 (70.0%)
Escaich et al., 1991 direct plasma PBMC
co-culture
n.d. n.d. 30/154 (19.5%)
Dictor et al., 2001 direct plasma PBMC
co-culture
6/16 (37.5%) 7/14 (50%) 3/3 (100%)
Tedder et al., 1998 direct plasma PBMC
co-culture
14/68 (20.6%) 2/6 (33.3%) n.d.
Andreoni et al., 1992 direct plasma PBMC
co-culture
n.d. n.d. 15/22 (68.2%)
Vella et al., 2000 direct plasma PBMC
co-culture
1/31 (3.2%) 1/21 (4.8%) 41/62 (66.1%)
Harrington et al., 2000 direct plasma PBMC
co-culture
0/3 (0%) 2/6 (33.3%) 2/14 (14.3%)
Sarmati et al., 1994 polyethylene glycol
treated plasma
n.d. n.d. 30/42 (71.4%)
Ercoli et al., 1995 polyethylene glycol
treated plasma
n.d. n.d. 170/202 (84.2%)
Andreoni et al., 1997 polyethylene glycol
treated plasma
n.d. n.d. 62/86 (72.1%)
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Sullivan et al., 1996). Nevertheless, virus isolations from
plasma samples with a viral load under 100000 HIV-1
RNA copies/ml have been only successful in a small
fraction of analyzed samples irrespective of the isolation
procedure used (Table 1).
To date, it remains unclear whether the bulk of plasma
virions is indeed noninfectious (due to inactivation by
immune defense or production of defective particles)
(Dianzani et al., 2002; Piatak et al., 1993b;Sullivan et
al., 1996) or if the inability to detect infectious particles in
patient plasma is a consequence of the relative insensitivity
of current methods used for virus isolation. The primary
goal of the current study was to devise a sensitive assay
system that allows quantification of infectious HIV-1
particles in plasma to define if the plasma virus pool
carries a substantial infectious load and to which extent
this pool of virions may participate in driving the infection
in vivo.Results
Polybrene induces effective capture of plasma-born HIV-1
to platelets
The primary intent of this study was to evaluate the
infectious virus load in plasma of HIV-1-infected individuals.
To this end, we sought to develop an improved assay strategy
that allows reliable quantitation of infectious virus load in
plasma.It has long been realized that polycationic reagents
such as polybrene can aid viral infection processes in
vitro by increasing viral attachment (Le Doux et al.,
2001; Manning et al., 1971; Pan et al., 1993; Toyoshima
and Vogt, 1969). However, polybrene is highly toxic for
cells and can be used only at concentrations below 20 Ag/
ml. Here we show that high concentrations of polybrene
are substantially more effective in promoting virus capture
to cells than conventionally used doses (Fig. 1). To be
able to utilize the improved virion attachment at high,
toxic polybrene concentrations, we adsorbed plasma viri-
ons in a first step to human platelets as ‘‘carrier’’ cells
that are subsequently washed free of plasma and poly-
brene, and co-cultured with the actual target cells, acti-
vated primary CD4+ T cells. We chose human platelets as
carrier cells for our assay development because these cells
bind HIV-1 but are not known to support productive
infection that should guarantee an optimal transmission
to the desired target cells, primary CD4+ T cells (Lee et
al., 1998, 1999; Youssefian et al., 2002). A further
advantage of platelets is their small size and their higher
surface to volume ratio compared to other cell types. As a
consequence, high platelet numbers can be employed that
should allow an optimal distribution of virions on indi-
vidual cells, which is important for the quantification of
infectious titers.
We found that after exposing human platelets for 4 h to
seronegative human plasma spiked with either the R5
primary virus JR-CSF or the X4 primary virus 2044, only
16.8% of the R5 virus and 9.2% of the X4 virus had
spontaneously bound to platelets as measured by deposition
Fig. 1. Polybrene induces HIV capture to platelets and increases infectivity. (a) Seronegative plasma was spiked with 10 ng p24 of JR-CSF (grey bars) or 2044
(black bars) and reacted with platelets and increasing concentrations of polybrene for 4 h. Platelet-associated virus was then determined by measuring p24
antigen levels. Bars represent means of duplicate wells (F SD). Results from one of two experiments are shown. (b) Plasma was spiked with indicated virus
isolates (10 ng p24) and incubated with platelets in the presence (right) or absence (left) of 2 mg/ml polybrene as described above. p24 antigen associated with
platelets (black bar) or remaining unbound in the supernatant (grey bar) was determined. Bars represent means of duplicate samples. (c) Identical amounts of
indicated virus stocks were titrated as free virus (grey bars) or after binding to platelets (black bars) on stimulated healthy donor CD8-depleteted PBMC and
TCID50 determined.
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increasing concentrations of polybrene during the adsorp-
tion step, we were able to improve the capture efficiency
to approximately 80% for both viruses. Maximum capture
was reached at polybrene concentrations between 0.5 and
4 mg/ml.
Viral phenotype has no effect on capture efficiency
To rule out that our capture protocol selects for a
specific viral phenotype, we evaluated the efficiency ofR5, R5X4, and X4 virus adsorption to platelets in the
presence of polybrene (Fig. 1b). Seronegative plasma was
spiked with the indicated HIV isolates and binding effi-
ciency evaluated by measuring p24 antigen associated with
platelets. No differences in the capture of R5, R5X4, and
X4 viruses were observed. When polybrene (2 mg/ml) was
added during the plasma incubation step, 91.4 F 5.0%
(SD) of the added p24 antigen was associated with platelets
while 12.3 F 3.6% (SD) of p24 antigen remained unbound
in the supernatant. In contrast, when the adsorption was
carried out in the absence of polybrene, only 4.6 F 1.9%
P. Rusert et al. / Virology 326 (2004) 113–129116(SD) of the p24 antigen was associated with platelets and
79.4 F 17.6% (SD) of p24 antigen remained unbound.
Platelet-captured virions are highly infectious
We next compared the in vitro infectivity of platelet bound
to free virions using a panel of six virus isolates with different
co-receptor usage (Fig. 1c). To define solely the impact of
platelet-capture on infectivity, titrations were carried out in
culture medium in the absence of human plasma. We found
that platelet-immobilized virions were remarkably more
infectious than free virus. The increase in infectivity upon
immobilization to platelets ranged from 17- to 1413-fold
(median = 90-fold; mean = 382-fold). It has been previously
shown that positively charged compounds such as polybrene
can potently inhibit X4 virus infectivity (Haraguchi et al.,
1997; Trkola et al., 1999). Considering the high concentra-
tions of polybrene used for viral capture, it was therefore of
importance to ensure that residual polybrene bound to plate-
lets had no adverse effects on the infection process of X4
viruses. As depicted in Fig. 1c, we found no difference in the
transmission efficiency between different viral phenotypes.Fig. 2. Mechanism of polybrene-induced HIV binding to platelets. (a) The R5X4
platelets in the presence of 2 mg/ml polybrene for the indicated time and p24 anti
2044 (grey) to platelets was carried out either in medium alone or in the presence o
2044), and 50 Ag/ml of Mab 2F5. Capture of virions to platelets was estimated
addition of polybrene (2 mg/ml) and chondroitinsulfate (CS, 200 Ag/ml) at variable
simultaneously. Conditions 3–4: virus was reacted with polybrene (2 mg/ml)
concentration of 10 Ag/ml. Conditions 5–7: platelets were first pretreated with poly
(in case of condition 7) polybrene was added.Thus, residual polybrene bound to platelets does not interfere
with the infection process and virions are effectively captured
and transmitted by polybrene-treated platelets irrespective of
their co-receptor usage.
Timing and mode of virion capture to platelets
We next investigated the underlying mechanisms of the
capture process induced by polybrene. We found that the
polybrene-triggered binding of virions to the platelet mem-
brane is a surprisingly rapid process (Fig. 2a). Within 15
min, already 65% of the R5-using virus Pat 5, and 66.5% of
the X4-using virus Pat 19, had bound to the platelet
membrane. Maximum capture was reached after 4 h. To
probe if a specific interaction between viral envelope
proteins and known receptors for HIV-1 occurs, we tested
if a neutralizing antibody directed against the viral envelope
proteins gp41 (2F5), the soluble CD4 molecule CD4-IgG2,
which binds to gp120, or antibodies directed against CCR5
(PA14) and CXCR4 (12G5) inhibited virus binding to
platelets. As shown in Fig. 2b, none of these reagents had
an influence on virion capture induced by polybrene.isolate Pat 5 (black) and the X4 isolate Pat 19 (grey) were incubated with
gen associated with platelets determined. (b) Capture of JR-CSF (black) or
f 25 Ag/ml CD4-IgG2, 25 Ag/ml PA14 (for JR-CSF), or 50 Ag/ml 12G5 (for
by measuring p24 antigen. (c) Virus (SF162) was bound to platelets after
steps of the incubation procedure. Conditions 1–2: all reagents were added
, after addition of platelets volume was increased to a final polybrene
brene, then washed, incubated with CS, and washed again before virus, and
Fig. 3. Capture of HIV from patient plasma to platelets. (a) Virus from 14
plasma specimens was concentrated by high-speed centrifugation (hatched
bars) or captured to platelets in the presence (black bars) or absence (grey
bars) of polybrene and copies of viral RNA/ml plasma measured by real-
time PCR. (b) Quantities of virus measured after high-speed centrifugation
(open squares) and after capture to platelets with (full triangle) and without
polybrene (open triangle) were compared using Wilcoxon signed rank test.
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pound, a postulated mechanism of its action in promoting
virus adsorption is cross-linking of negative charges on
virus and cell membranes (Donato et al., 1996; Le Doux
et al., 2001). To probe if this is also the case for HIV-1
adsorption to platelets, we investigated if addition of neg-
atively charged compounds can inhibit the effect of poly-
brene. To this end, we added the highly negatively charged
glycosaminoglycan chondroitinsulfate (CS) at various steps
of the binding process (Fig. 2c). When CS was added during
the incubation of virus with platelets and polybrene, the
capture of virions to platelets was reduced from 81 F 8% to
15 F 0.5% (SD). A similar reduction in capture efficiency
was found when virus stocks, which were pretreated with
polybrene, were allowed to bind to platelets in the presence
or absence of CS. Equally, platelets pretreated with poly-
brene captured 56 F 4% (SD) of virions in the absence of
unbound polybrene in the medium. However, when these
polybrene-pretreated platelets were exposed to CS, only 1F
0% (SD) of the input virus was captured. Of note, this low
capture efficiency was reversed when polybrene was added
back during the incubation with the virus. Taken together,
these analyses strongly suggest that capture of virions to
platelet membranes promoted by polybrene involves a
cross-linking of negative charges on virion and cell mem-
branes via the positively charged compound.
Assessment of virion capture from patient plasma by
real-time PCR
Studying virion binding to cells by measuring p24 antigen
deposition has limitations: not all p24 antigen in virus
preparations is virion associated. Free p24 antigen is known
to spontaneously bind to cell membranes (Marechal et al.,
1998; Mondor et al., 1998) and might therefore influence the
readout in the p24 antigen binding assay. Moreover, the
sensitivity of the p24 antigen ELISA (1–10 pg/ml) is too
low to perform direct binding studies with plasma from HIV-
infected individuals. A viral load of 100000 RNA copies/ml
plasma corresponds to approximately 10 pg of p24 antigen
(Chertova et al., 2002), and thus p24 antigen concentration in
most patients samples would be under or close to the
detection limit of the ELISA assay.
To verify our data obtained in the p24 antigen binding
assay and to investigate if the virion capture procedure is also
successful in retrieving virus from patient plasma, we mea-
sured virion adsorption to platelets by real-time PCR in
plasma samples from 14 HIV-1 infected individuals (Fig.
3a and Table 2). The efficacy of virion attachment to platelets
in the presence and absence of polybrene was evaluated and
compared to the total number of RNA copies in the respective
patient plasma. The latter was determined from viral pellets
derived after high speed centrifugation of plasma. We found
that polybrene induced a highly effective adsorption of HIV-1
to platelets. Quantities of virus measured after high speed
centrifugation and after capture to polybrene-treated plateletswere not significantly different (P = 0.2412 Wilcoxon signed
rank test; Fig. 3b). In agreement with our data obtained in the
p24 antigen binding studies, we found that in the absence of
polybrene, HIV-1 binding to platelets was significantly lower
(P < 0.0001). Compared to RNA copy numbers after high-
speed centrifugation, median recovery after capture to plate-
lets in the presence or absence of polybrene were 95% and
5%, respectively.
Quantification of infectious HIV-1 plasma viral load using
platelet-immobilized virions
We next compared the sensitivity of our new plasma
virus titration assay with the commonly used protocol (The
Division of AIDS, National Institute of Allergy and Infec-
tious Diseases and National Institute of Health, 1997) that is
based on direct co-culturing of plasma and target cells.
Human plasma spiked with increasing concentrations of
Table 2
Quantification of infectious virus load in patient plasma
Patient Age
(years)
Gender Clinical
stage
Therapy Isolation
day
CD4
cells/mm3
RNA
(copies/ml)
Infectious titer
(TCID50/ml plasma)
Ratio infectious
to total particlesa
Co-receptor
usage
1 32 m A3 no 29.03.01 182 73,787 107.15 689 X4
2 49 m C3 no 24.08.01 6 148,562 46.77 3176 R5X4
3 39 f n.a. no 05.04.01 298 116,844 107.15 1090 R5
5 37 m C3 no 06.04.01 218 11,832 8.91 1328 R5X4
7 62 m C3 no 09.04.01 16 232,421 398.11 584 R5
9 42 m C3 no 17.04.01 146,220 26.92 5433 R5
10 52 m n.a. no 24.04.01 80 220,000 3.98 55262 X4
11 50 m C3 no 12.06.01 63 75,840 61.66 1230 X4
13 40 m C3 no 27.04.01 373 330,454 186.21 1775 R5
15 69 m A3 no 07.05.01 210 62,926 3.98 15806 R5X4
16 36 f C3 no 28.05.01 97 124,244 2.29 54234 R5X4
18 40 m A2 no 28.06.01 488 131,431 275.42 477 R5
19 48 m C3 no 02.07.01 188 73,889 20.42 3619 X4
20 40 m A2 no 04.07.01 335 285,804 < 2.29 n.a. n.a.
29 39 m A2 no 13.05.02 224 82,300 22.39 3676 R5
31 41 m C3 no 14.05.02 431 86,900 5.25 16558 R5
33 40 m A2 no 29.05.02 325 101,500 15.49 6553 R5
34 64 m A3 no 15.07.02 64 144,000 186.21 773 n.i.
35 50 m A3 no 15.08.02 312 105,000 5.25 20007 R5
36 36 m A2 no 16.08.02 247 17,400 5.25 3316 R5
37 43 m B1 no 19.08.02 417 30,700 8.91 3445 n.d.
38 31 m n.a. no 23.08.02 170 66,000 81.28 812 R5
39 36 m A1 no 23.08.02 364 163,500 26.92 6075 R5X4
42 41 m B3 no 12.09.02 197 178,500 35.48 5031 R5
43 41 m A2 no 12.09.02 308 199,500 81.28 2454 R5
44 52 m C2 no 19.09.02 196 115,000 20.42 5632 R5X4
47 46 m A2 no 04.12.02 475 757 < 2.29 n.a. n.a.
48 35 m C3 no 04.12.02 630 330 < 2.29 n.a. n.a.
51 36 m B2 no 06.12.02 407 3130 2.29 1366 R5
53 42 m A2 no 09.12.02 683 8170 < 2.29 n.a. n.a.
55 24 m A1 no 13.12.02 464 2290 < 2.29 n.a. n.a.
60 36 m A2 no 19.12.02 400 18,500 < 2.29 n.a. n.a.
61 27 m A1 no 19.12.02 704 4470 < 2.29 n.a. n.a.
63 26 m A3 no 06.01.03 76 12,800 7.94 1611 R5X4
64 40 m A2 no 13.01.03 338 13,900 7.94 1750 R5
65 40 m A1 no 16.01.03 410 40,900 < 2.29 n.a. n.a.
66 35 f A3 no 31.01.03 197 2930 < 2.29 n.a. n.a.
67 23 m B3 no 19.02.03 9 389,000 416.87 933 n.i.
68 40 m A2 no 19.02.03 328 64,650 < 2.29 n.a. n.a.
69 31 m B3 no 20.02.03 50 1,310,000 416.87 3142 R5
70 29 m C3 no 24.02.03 32 815,000 6.92 117803 X4
71 50 m B3 no 27.02.03 113 144,000 6.92 20814 R5
72 41 m B3 no 28.02.03 104 155,000 6.92 22404 R5
107 48 f A2 no 18.12.02 382 2250 < 2.29 n.a. n.a.
113 62 m B2 no 07.11.02 629 74,900 26.92 2783 R5
114 33 m A1 no 17.06.03 811 17,603 3.38 5208 R5
115 36 m A1 no 10.12.02 625 5490 < 2.29 n.a. n.a.
117 37 f A2 no 19.12.02 336 4560 < 2.29 n.a. n.a.
121 40 f A2 no 18.12.02 242 11,200 < 2.29 n.a. n.a.
122 44 m A2 no 04.12.02 511 43,400 2.29 18945 R5
125 37 f A2 no 16.12.02 750 2350 < 2.29 n.a. n.a.
130 70 m A1 no 06.12.02 768 < 50 < 2.29 n.a. n.a.
a Corresponds to TCID50 per two RNA copies.
n.d., not done; n.a., not applicable.
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depicted in Fig. 4a, the new assay yielded a 1–3 log higher
infectivity at all input concentrations tested. While cultures
in the direct plasma co-cultures remained negative up to an
input of 30 pg of virus (measured as p24 antigen), theplatelet-cross-linked samples were positive even at the
lowest concentration tested (0.3 pg). We found a mean
333-fold increase in sensitivity over the traditional proce-
dure when virion capture to platelets was performed with
isolates JR-CSF, DH123, and 2044 as representatives of R5,
Fig. 4. Platelet cross-linking increases sensitivity of plasma titration. (a)
Plasma spiked with the indicated concentration of the R5 virus JR-CSF was
titrated using the standard plasma–co-culture protocol (circles) and
compared to spiked plasma titrated by the platelet cross-linking protocol
(squares). One of three independent experiments is shown. (b) Comparison
of TCID50 of plasma spiked with isolates JR-CSF (121.1 pg), DH123 (2.7
pg), and 2044 (1.8 pg) after using the standard plasma–co-culture protocol
(hatched bars) and the platelet cross-linking protocol (black bars). (c)
Plasma spiked with virus JR-CSF (1.8 pg p24/ml) was titrated using the
platelet cross-linking protocol on three different target cell preparations
(donors A, B, and C). Bars depict means of three titration assays per donor
cells. TCID50 on days 7 and 14 was compared using ANOVA (Kruskal–
Wallis test with Dunn’s multiple comparison test).
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To evaluate the reproducibility of the new plasma titration
protocol, seronegative human plasma was spiked with the
R5 isolate JR-CSF and stored in aliquots at 80 jC. The
spiked plasma was then titrated on three different donor cell
preparations. As shown in Fig. 4c, on day 7 postinfection,
the measured TCID50 in three independent assays showed
some variation that is not unexpected due to the known
variability of primary donor cells in supporting HIV infec-
tion. However, these differences were not statistically sig-
nificant and influences of the donor cells on the
determination of infectious titers were negligible after 14
days of culturing. Taken together, our novel assay providesa 1–3 log increase in sensitivity over traditional protocols
by boosting the viral attachment process and diminishing
cytostatic effects of plasma on target cells. Equally impor-
tant, the assay is highly reproducible and due to its sensi-
tivity allows a reliable quantification of infectious units in
frozen plasma samples.
Virus isolated from plasma represents current quasispecies
Autologous patient virus is commonly isolated from
PBMC because isolations from plasma have in general been
less successful (The Division of AIDS, National Institute of
Allergy and Infectious Diseases and National Institute of
Health, 1997). However, sequence analysis of virus quasis-
pecies present in plasma and of virus isolates derived from
PBMC has shown that viral isolates derived upon activation
of cells do not always reflect the most recently produced virus
strains (Gunthard et al., 1998; Havlir et al., 1996; Wei et al.,
1995). To validate our virus isolation protocol, we isolated
virus from three patients at several time points from PBMC
and from plasma using our new protocol. We then compared
viral envelope sequences of these viral isolates with envelope
sequences derived directly from plasma and PBMC to probe
which isolation procedure represents best the actively repli-
cating virus population (Fig. 5). Fifteen to 16 individual
clones derived after RT-PCR of viral RNA from each spec-
imen were available for phylogenetic analysis. Sequences
that represented clusters within one patient were grouped and
distribution of these clusters in plasma and PBMC specimen
analyzed. Patient 113 was infected with a rather heteroge-
neous virus population. Nonetheless, clustering did not reach
significance level. Sequences spanning the C2-V3 region
belonged to the same quasispecies in all specimen analyzed at
the first time point and the same virus population was also
dominant at the second time point analyzed. We also found a
dominant viral quasispecies in the plasma of patient 120 (13
out of 16 clones), which was the sole viral population isolated
from both plasma and PBMC cultures. Net divergences
between plasma and plasma culture as well as between
plasma and PBMC culture were very low in these two
patients (range 0.0–0.4%). The most variable virus popula-
tion was found in patient 109. Several virus quasispecies were
present in plasma and plasma culture at the earliest time point
analyzed. However, net divergence was only 0.7%. Note-
worthy, between the first and second time point analyzed, this
patient had been on antiretroviral treatment, which was
interrupted 2 weeks before the second time point (Oxenius
et al., 2002). At that time, the population emerging in the
plasma was also isolated from plasma culture but not from
PBMC culture. Net divergence from plasma was 1.3% and
4.7% for plasma culture and PBMC culture, respectively.
Five months later, a different quasispecies was dominant in
plasma that had already been present in the earliest plasma
sample analyzed. Again, a matching population was well
represented in the plasma culture isolate (divergence 0.01%).
At the last time point analyzed for patient 109, identical virus
Fig. 5. Phylogenetic analysis. Phylogenetic analyses of HIV-1 envelope sequences encompassing the C2 and V3 domains from 15 to 16 individual clones
derived after RT-PCR of viral RNA that was obtained directly from plasma and patient PBMC or from viral isolates derived from plasma and PBMC cultures
were performed using the software package PHYLIP version 3.6. Samples from three patients were analyzed separately (Table 2). Boxes indicate the individual
clones. Sequences that clustered with quasispecies present in one patient are shown in the same color code. Blank boxes with a circle indicate single clones that
differed significantly from other quasispecies found within this patient.
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the virus population isolated from plasma. However, the virus
isolate derived from PBMC after stimulation of cells did not
represent clones that were actively replicating at this time
point but likely reflected a reactivated ancestral strain. The
corresponding net divergences were 0.06% for the plasma
culture and 3.9% for the PBMC culture, respectively.
Taken together, our isolation procedure yields virus
isolates that on large represent the current replicating virus
pool in plasma whereas, as described previously, virus
isolation from PBMC can lead to the reactivation of latent,
ancestral strains.
Infectious virus load at different disease stages
We next determined the efficiency of our procedure in
isolating infectious virus from plasma of 52 patients atvarious disease stages (Table 2). Plasma virus loads of
analyzed samples ranged from <50 to 1310000 RNA co-
pies per ml (median = 73838; mean = 124465). We
successfully isolated plasma virus in 36 out of the 52
samples analyzed. The overall success rate in isolating
virus from plasma was 69%. No virus could be isolated at
viral loads below 1000 copies/ml (zero out of three
samples). Eleven percent (1/9) of plasma samples with
1000–10000 RNA copies/ml, 70% (7/10) of samples with
10000–50000 copies/ml, 89% (8/9) at loads between
50000–100000 copies/ml and above 100000 copies/ml
95% (20/21) of samples yielded positive cultures. None of
the previously published plasma isolation assays had a
comparable sensitivity in isolating infectious virus from
high and low viral load plasma (Table 1).
In a next step, we determined the infectivity (TCID50)
of these plasma samples (Table 2) and investigated the
Fig. 7. Immune complexes stay intact during plasma titration. Virus
(SF162, 150 TCID50) was incubated with the neutralizing anti-gp41 Mabs
2F5 and 4E10 (50 Ag/ml each), the neutralizing anti-gp120 Mabs 2G12
(50 Ag/ml) and IgG1b12 (10 Ag/ml), and the tetrameric CD4 molecule
CD4-IgG2 (50 Ag/ml) for 1 h at 37 jC. Immunocomplexed viruses were
then titrated using the platelet-cross-linking protocol. One of two
independent assays is shown. The percentages of infectious titer (TCID50)
obtained in the untreated control are depicted.
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load as measured by RNA copies in plasma. Infectious
doses ranged from <2.29 to 417 TCID50/ml plasma and
correlated strongly with the total viral load (Fig. 6).
Correlations remained significant when only samples that
gave a positive result in the infectivity assay were used.
Both total and infectious viral load correlated inversely
with the CD4 count (r2 = 0.4041, P < 0.0001 and r2 =
0.2694, P < 0.0001, respectively). No disparity in infec-
tious titers obtained from patients infected with R5 or X4
was observed. Viral RNA copies per TCID50 ranged from
477.2 to 117803 (mean 11550 copies/TCID50). Up to now
it has been unclear whether the low infectivity measured in
patient plasma reflects accurately the in vivo situation or is
a result of inadequate assay systems. Using this boosted in
vitro culturing system, we found a higher degree of
infectivity in patient plasma than previously reported.
Nevertheless, infectious titers remained low compared to
the total amount of viral RNA copies detected. Thus, even
with our boosted infection procedure, HIV particles in
plasma are predominantly noninfectious.
Virus infectivity and antivirals
Low infectious to noninfectious particle ratios may
reflect the production of genetically defective particles
(Piatak et al., 1993b) or be a result of active immune
defense. So it has been shown that the majority of HIV-1
particles found in patient plasma is immune complexed by
antibodies and complement (Dianzani et al., 2002; Stoiber
et al., 2001). To what extent these immune complexed
viruses remain infectious is currently not known, but it is
feasible that differences in infectious titers between
patients could in part be due to differences in the activityFig. 6. Characterization of infectious virus pool in patient plasma. The
infectious titer (TCID50) of plasma samples from 51 chronically infected
patients (see Table 2) was determined using the platelet-cross-linking
protocol. Correlation analysis of log TCID50 in plasma and log virus load
(total number RNA copies per ml) is shown. Co-receptor usage of isolates
is indicated R5 user (circle), X4 user (square), R5X4 user (closed triangle),
isolates with undetermined co-receptor usage (open triangle).of autologous neutralization antibodies. Of note, we found
that virus treated with neutralizing antibodies or tetrameric
CD4-IgG2 before cross-linking to platelets remained non-
infectious (Fig. 7), indicating that immune complexes stay
intact during the cross-linking process. Therefore, it is
possible to use our method to evaluate the in vivo impact
of neutralizing antibodies or other antiretrovirals that affect
virion infectivity directly.
To explore to what extent viral infectivity fluctuates
over extended time periods, we analyzed infectious titers
and total plasma viral load in three chronically HIV-1-
infected patients over a time period of 3–4 months. We
found that ratios between total and infectious viral load
varied considerably between patients (Table 2), but were
characteristic for a patient over extended time periods
(Fig. 8). We further determined the infectious titer of four
patients harboring partially ART-resistant HIV who re-
ceived in addition to a combination of reverse transcrip-
tase and protease inhibitors the fusion inhibitor T-20
(Table 2 and Fig. 9). Upon receiving T-20, patients 9
and 11 decreased viral loads by several logs. Concurrent-
ly, infectious titers dropped to undetectable levels in both
patients. Only a moderate reduction in viral load (0.95
logs) was observed in patient 19 that was reflected by a
2.95-fold decrease in infectious titer. Interestingly, patient
7 failed to reduce viral loads in response to T-20
treatment. However, while total viral loads were main-
tained, viral infectivity showed a decline from 398 to 27
TCID50/ml and CD4 cell levels increased from 16 to 34,
indicating that this patient’s virus was not completely
resistant to T-20. These findings underline the potential of
monitoring plasma infectivity in parallel to total viral
Fig. 8. Longitudinal evaluation of infectious virus load in patient plasma. The infectious titer (TCID50) of plasma samples from three chronically infected
patients (see Table 2) was determined using the platelet-cross-linking protocol. TCID50 per ml plasma (circles) and virus load (total number RNA copies per ml;
triangles) are shown.
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virals that target virions directly and modulate their
infectivity.Discussion
Quantitation of virus particles in patient plasma is due to
the easy accessibility of this compartment and the sensitivity
of the assays, the commonly evaluated virologic marker for
the assessment of disease progression and effects of thera-
peutic intervention. However, current methods routinely
used for viral load measurements determine the amount of
genomic HIV-1 RNA copy numbers but cannot distinguish
between infectious and noninfectious or neutralized par-ticles in plasma (Coombs et al., 1993; Mellors et al., 1997;
Piatak et al., 1993b).
The infectious virus load in plasma of HIV-1-infected
individuals is traditionally measured by co-culturing serial
dilutions of patient plasma with stimulated healthy donor
PBMC (Andreoni et al., 1997; Coombs et al., 1989;
Escaich et al., 1991; Ho et al., 1989; Lathey et al., 1994;
Pan et al., 1993; Piatak et al., 1993a, 1993b; The Division
of AIDS, National Institute of Allergy and Infectious
Diseases and National Institute of Health, 1997; Vella et
al., 2000). However, virus isolations from patient plasma
have been on large less successful than virus isolations
from cellular material. Despite high viral copy numbers in
plasma, only a minor fraction of these HIV-1 particles were
described to be infectious (Dianzani et al., 2002). Whether
Fig. 9. Infectious virus load during antiretroviral treatment. The TCID50 of plasma from four chronically infected patients (see Table 2) receiving antiretroviral
treatment in combination with the fusion inhibitor T-20 was determined. TCID50 per ml plasma (circles), virus load (total number RNA copies per ml; squares),
and absolute CD4 T cell levels per mm3 blood (triangles) are shown.
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majority of the virions found in plasma are noninfectious
particles remains uncertain. The objective of the present
study was to develop a reliable and sensitive protocol for
the quantification of HIV-1 virus particles from patient
plasma that allows to investigate the relative contribution
of the plasma virus pool in maintaining and spreading the
infection.
There are numerous technical factors that limit the
success of virus isolation from plasma. Foremost, plasma
at high concentration can clot upon co-cultivation with
target cells, and this gel formation can substantially dimin-
ish infectability by reducing cell viability and motility in the
culture system ((Lathey et al., 1994; Pan et al., 1993; The
Division of AIDS, National Institute of Allergy and Infec-
tious Diseases and National Institute of Health, 1997) and
data not shown). Secondly, residual antiviral factors in
patients plasma such as neutralizing antibodies, comple-
ment, chemokines, cytokines, or drugs can affect the success
of virus isolation (Lathey et al., 1994; Pan et al., 1993).
Lastly, as with all assays that utilize human PBMC as target
cells, a considerable variability due to differences in infect-
ability among donor cells can occur.
Entry of HIV-1 into host cells requires binding of the
viral envelope protein to the primary receptor CD4 and a
fusion co-receptor, which belongs to the chemokine receptor
family, most commonly the chemokine receptor CCR5 and
CXCR4. Besides these entry receptors, several other cell
surface molecules such as adhesion molecules (Fortin et al.,
1997), gycosaminoglycan side chains of proteoglycans
(Mondor et al., 1998; Ohshiro et al., 1996; Patel et al.,
1993; Saphire et al., 2001; Ugolini et al., 1999), and lectins
(Geijtenbeek and van Kooyk, 2003) have been identified
that function as auxiliary receptors aiding viral attachmentto target cells by interacting with either viral- or host-
derived proteins on the virion surface.
The rate-limiting step in the penetration of target cells by
HIV-1 is considered to be the attachment of the virion to the
cell surface, not the subsequent binding to the receptors or
the fusion reaction (Orloff et al., 1991). Accordingly, it has
been shown that by increasing viral attachment by employ-
ing centrifugal forces, in vitro infection rates can be sub-
stantially boosted (Ho et al., 1993; O’Doherty et al., 2000;
Pietroboni et al., 1989). However, the necessary centrifuga-
tion steps are time consuming and do not allow for process-
ing of larger sample numbers.
The essence of the method introduced here is that virus
particles are bound to carrier cell membranes that allow a
quick and reliable separation of virus particles from plasma.
Thereby we achieve the following: (i) the infection process
occurs in the absence of patient plasma. Thus, factors
present in plasma that inhibit infection are removed. (ii)
Virus particles are cross-linked to cell membranes which
increase sedimentation rates compared to cell-free virus
preparations and thereby aid the attachment and subsequent
infection process.
The assay utilizes the polycationic sugar polybrene to
cross-link virions to platelets as carrier cells. Subsequent
culturing of immobilized virus with stimulated healthy
donor PBMC yields 1–3 log higher infection rates than
direct co-culturing of infectious plasma with target cells.
Binding of virions to platelets induced by polybrene does
not involve interaction with CD4 and co-receptors nor did
we observe a direct involvement of the viral envelope
proteins in this process. We provide evidence that the
positively charged compound polybrene cross-links nega-
tive charges on virion and cell surface and thereby pro-
motes viral attachment. This cross-linking process is highly
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by this method. Of note, we have also found that the same
method can be used to increase infectivity of other retro-
viral vectors, irrespective of which cellular receptors are
utilized for entry (data not shown). Most importantly, the
cross-linked virions are highly infectious and are efficiently
transferred to susceptible target cells. We found that
platelet immobilized virions are 1–3 logs more infectious
than free virus particles. The degree of infectivity enhance-
ment seen was fairly consistent when samples from a
specific individual were measured but varied among pa-
tient isolates. Therefore, the assay will be most useful for
longitudinal monitoring of intra-patient changes in viral
infectivity.
A specific advantage is that using our new method,
infectious virus can be isolated from patient plasma with a
higher success rate than described with previously reported
assay systems (Table 1). As noted above, a general problem
in all assay types that employ primary human PBMC as
target cells is the vast variability in susceptibility to HIV
infection among donor cells. Here we show that using cell
pools from three donors in combination with our enhanced
infection protocol allows a reliable and highly reproducible
quantification of virus titers in patient plasma. Due to its
increased sensitivity, the assay also allows a reliable quan-
tification of the infectious virus load in frozen plasma
samples. We have also used the same virus capture method
to increase infectivity of virus on various cell lines with a
similar success in boosting infectivity (data not shown).
Up to now, replication-competent, infectious virus is more
frequently isolated and quantified from patient PBMC be-
cause virus isolations from plasma have been on large less
successful (Pan et al., 1993; The Division of AIDS, National
Institute of Allergy and Infectious Diseases and National
Institute of Health, 1997). Although the number of infected
cells in the periphery reflects cell-free viral loads under
ongoing viral replication, isolating virus from patient cells
bears the risk of reactivating latent, ancestral viral strains. So
it has been shown that viral isolates derived upon activation
of cells do not always yield the most recently produced virus
isolates and appearance of mutant viruses in plasma may
precede the manifestation of these quasispecies in cells of the
periphery by several weeks (Gunthard et al., 1998; Havlir et
al., 1996; Wei et al., 1995). Particularly when studying
responses to novel therapies, a rapid and exact determination
of escape mutants is critical and methods that allow a reliable
and sensitive isolation of viruses from plasma are therefore
sought for. Here we show that our novel isolation procedure
successfully derives replication-competent virions from plas-
ma. The isolated quasispecies reflected the dominant viral
variants present in the patient’s plasma at the given time point
whereas virus isolated from PBMC can include reactivated
ancestral variants. Given the increased sensitivity in both
virus isolation and quantification, our assay may become a
useful tool in monitoring effects of novel drug regimens and
vaccination strategies on virion infectivity. Measuring effectson virion infectivity might be particularly informative when
effects of substances that target virions directly, such as
neutralizing antibodies, are tested.
Most importantly, our newly developed assay allowed us
to get insights into the infectivity of virions in human
plasma in vivo. Little is known about the ratio of infectious
to noninfectious virus in plasma of HIV-1-infected patients
and how this ratio evolves throughout pathogenesis. Here
we show that infectious to noninfectious ratios vary sub-
stantially between patients but are characteristic for an
individual for extended time periods. It has been suggested
that the majority of virions present in plasma have been
actively combated by the immune system and are com-
plexed by antibodies and complement (Dianzani et al.,
2002; Stoiber et al., 2001). To what extent these immune
complexed viruses maintain their infectivity is not known,
and whether a high disparity between infectious titers and
total viral loads reflects higher degrees of immune defense
or production of defective particles bears further investiga-
tion. Our data indicate that the immobilization procedure
used in our assay does not interfere with viral entry and does
not restore the infectivity of neutralized virus. Thus, this
assay allows an accurate quantitation of infectious particles.
Due to the rapid replication and the high mutation rate of
HIV-1, a substantial proportion of the virus particles in
plasma will also comprise defective virions (Perelson,
2002). It has been a longstanding debate whether HIV-1
spread in vivo occurs mainly through cell–cell or free
virus–cell transmission. Recent findings have shown that
viral transmission in vivo occurs between cells near the so-
called viral synapses (Jolly et al., 2004; McDonald et al.,
2003; Zhang et al., 2004). To what extent replication-
competent, infectious particles are present in plasma and
contribute to the maintenance of the infection in vivo is not
known. Virus production rates of infected cells in the
periphery have been estimated to be in the range of 100–
10000 RNA copies per infected cell per day (Funk et al.,
2001; Hockett et al., 1999; Stafford et al., 2000). Here we
show using our boosted infection assay that viral infectivity
in plasma is indeed exorbitantly low and that on average
only one infectious dose per 5775 viral particles (11550
HIV-1 RNA copies) is found. It is possible that our assay
may still underestimate the in vitro infectivity of patient
plasma and that more sensitive assays may be devised.
However, when taking our data on viral infectivity as
measure, this would mean that on average less than one
infectious unit is produced by an infected cell. Because it
cannot be expected that each infectious particle will succeed
in infecting a new target cell, it is unclear how the infection
in vivo would be maintained on such low infectivities given
the infection process in vivo indeed depends on viral
transmission in plasma. There are several possible explan-
ations to this finding: firstly, should free virus transmission
in plasma play a substantial role in vivo, then this can only
be the case if either viral infectivity is higher than measured
in our assay or alternatively, viral productions rates are
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can be speculated that the viral compartment in plasma may
only play a subordinate role in vivo and that as previously
suggested cell–cell transmission in infected tissue is indeed
more efficient in driving viral spread in vivo (Jolly et al.,
2004; McDonald et al., 2003; Zhang et al., 2004).Materials and methods
Reagents
MAbs 2F5 (Muster et al., 1993) and 2G12 (Trkola et al.,
1996) were gifts from H. Katinger. Mab IgG1b12 (Burton
et al., 1994) was provided from D. Burton. Mab 12G5 was
from Pharmingen and the CD4-IgG2 molecule and Mab
PA14 were from P. Maddon (Allaway et al., 1995). The
following reagents were purchased from Sigma: Polybrene
(Hexadimethrine bromide), HEPES buffer, chondroitin sul-
fate (CS), phytohemagglutinin (PHA).
Stimulated CD8 depleted PBMC
Buffy coats obtained from three healthy blood donors
were depleted of CD8+ T cells using Rosette Sep cocktail
(StemCell Technologies Inc.) and PBMC isolated by Ficoll-
Hypaque centrifugation. Cells were adjusted to 4  106 per
ml in culture medium (RPMI 1640, 10% FCS, 100 U/ml IL-
2 (NIAID repository), glutamine, and antibiotics), divided
into three parts, and stimulated with either 5 Ag/ml PHA, 0.5
Ag/ml PHA, or anti-CD3 Mab OKT3. After 72 h, equal
numbers of CD8-depleted PBMC stimulated by one of these
three methods were combined and are called stimulated
CD8-depleted PBMC.
Platelet preparation from healthy donors
Platelets were obtained from HIV-negative, healthy
blood donors. Blood was collected into EDTA vacutainer
vials (Becton Dickinson) and centrifuged at 550  g for 15
min. The top layer containing platelet-rich plasma was
collected and platelet counts determined using an AcT diff
analyzer (Beckman Coulter). Platelet-rich plasma was then
aliquoted in 1.5 ml Sarstaedt tubes, stored at 70 jC, and
subsequently used as source of platelets.
Plasma collection from patient blood
Plasma sampled from patients at various disease stages
was included in the current study (Table 2). Unless otherwise
stated, these patients had not received antiviral therapy for
extended time periods before blood sampling due to various
clinical reasons. Informed consent was obtained from all
patients according to the guidelines of the University Hos-
pital Zurich. Patient blood was sampled in EDTA vacutainer
vials. Within 6 h after blood draw, platelet-rich plasma wascollected and frozen in 1-ml aliquots at 70 jC. We
preferred using frozen plasma because fresh plasma causes
the human platelets added to cross-link virions to form
aggregates that are difficult to resuspend and might therefore
not allow accurate titration of the infectious particles. Four
patients received a triple combination of antiviral drugs and
T-20 (Fig. 9). These individuals and patients displayed in
Fig. 8, where plasma sampling was not performed as
described above, were not included in the analysis depicted
in Fig. 6 and Table 1.
p24 antigen ELISA
HIV-1 p24 antigen concentrations were measured by an
in-house p24 antigen enzyme-linked immunosorbent assay
as described (Moore et al., 1994; Trkola et al., 1995).
Virus stocks
The origin of virus isolates JR-CSF (R5), DH123 (R5X4),
2044 (X4), and NL4-3 (X4) has been described (Adachi et al.,
1986; Koyanagi et al., 1987; Shibata et al., 1996; Simmons et
al., 1996). Virus isolates Pat 3 (R5), Pat 19 (X4), Pat 5 (R5X4)
Pat 109 (R5), Pat 113 (R5), and Pat 120 were obtained from
patient CD4+ T cells as described (Trkola et al., 2003; Wong
et al., 1997). Stocks from these viruses and viruses isolated
from plasma were grown and titrated on CD8-depleted
PBMC. The 50% tissue culture infectious dose (TCID50) of
virus stocks was determined by performing serial 5-fold
dilutions of 100 Al viral inoculum in eight replicates in a
96-well tissue culture plate and calculated using the method
of Reed andMuench (1938). In Fig. 1c, the same method was
used to determine the impact of platelet immobilization on
viral infectivity. In this case, equal amounts of virus inoculum
either in solution or immobilized to platelets were used. Co-
receptor usage of all virus isolates (see Table 2) was deter-
mined as described (Trkola et al., 1998).
Isolation and titration of HIV-1 from plasma samples
Thawed patient plasma was depleted from autologous
platelets and a constant number of donor platelets were added
to provide similar binding surfaces in all samples. Both too
low and too high carrier platelet numbers had adverse effects
on the isolation efficiency: low carrier platelet numbers
resulted in reduced virus capture whereas too high numbers
of platelets in the co-cultures were toxic for the target cells
(data not shown). HIV-1 in vivo can bind spontaneously to
platelets although to a low extent (data not shown). Thus,
removing autologous platelets before virus isolation is of
little consequence on the total virus load in the plasma
sample. Platelet-rich patient plasma (2 ml) from frozen stocks
was centrifuged for 10 min at 6000 g to remove autologous
platelets. Platelets of a seronegative donor were adjusted to 4
 108/ml in phosphate-buffered saline (PBS). To cross-link
virions to platelets, 250 Al of the platelet suspension was
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4 h at 37 jC in a 12-well culture plate (Nunc). The concen-
tration of polybrene in the diluted plasma was 2 mg/ml unless
otherwise stated. After the cross-linking step, samples were
transferred to microtubes and platelets collected by centrifu-
gation at 6000 g for 10 min. Platelets were washed once in
1 ml PBS and then resuspended in 900 Al culture medium
containing 20 mM HEPES buffer. Serial 1:3 dilution of this
platelet suspension was performed and 150 Al of the respec-
tive dilution was then co-cultured in quadruplicates with 1
106 stimulated CD8-depleted PBMCs in a 24-well culture
plate (final volume was 1 ml). Viral replication was moni-
tored by measuring p24 antigen production on days 7, 10, 14,
21, and 28 postinfection. Cultures were supplemented weekly
with fresh medium and 2.5  105 stimulated healthy donor
cells. TCID50 was determined using the method of Reed and
Muench (1938). Infectious titers reported refer to the infec-
tious doses measured on day 14. Using an input of total 2 ml
patient plasma in four replicate wells, theminimum infectious
dose that can be detected in our assay is 2.29 TCID50/ml.
To compare the newly developed assay with the com-
monly used method that employs direct co-culturing of
patient plasma and target cells, titrations were set up using
the protocol recommended by the Division of AIDS, Na-
tional Institute of Allergy and Infectious Diseases for use in
clinical trials (The Division of AIDS, National Institute of
Allergy and Infectious Diseases and National Institute of
Health, 1997).
Virus adsorption measured by p24 antigen deposition
Seronegative plasma (800 Al) or PBS was spiked with
HIV-1 isolates (approximately 10 ng p24/ml) and incubated
with 1.25  108 platelets and the indicated concentrations of
polybrene in PBS in a total volume of 1 ml. After incubation
for 4 h at 37 jC, the samples were centrifuged at 6000 g and
pellets washed once with PBS. Then, platelets were resus-
pended in 800 Al seronegative plasma (diluted 1:2 in PBS),
attached virions lysed by addition of 5% Empigen (Calbio-
chem; 200 Al), and p24 content measured by ELISA. Mock-
treated platelets were used to obtain background levels. All
samples were measured on the same ELISA plate in dupli-
cates and background subtracted. The 100% values
(corresponding to the p24 content of the spiked virus) were
determined by measuring p24 antigen concentration in a mix
of spiking virus, plasma, and 200 Al of 5% Empigen in a total
volume of 1 ml.
Virus adsorption measured by real-time PCR
Viral RNA was quantified as follows: virus from plasma
specimens was concentrated by high speed centrifugation at
50000  g and extracted using the RNAesy mini kit
(Qiagen Hilden, Germany). Platelet-bound viral prepara-
tions were extracted by a protocol utilizing phenol extrac-
tion and ethanol precipitation (RNAgents, Promega,Mannheim, Germany) because polybrene in these samples
precluded binding to silica matrices (data not shown).
Genomic HIV-1 RNAwas amplified in an i-cycler real-time
thermocycler (Biorad, Lucerne, Switzerland) and quantified
by comparison to an external standard curve utilizing
synthetic HIV-1 RNA. A highly sensitive one-tube RT
PCR protocol in which cDNA synthesis and PCR reagents
are separated by a wax layer and reunited by incubation at
high temperatures was used as previously described (Ros-
cic-Mrkic et al., 2003) utilizing the Qiagen one-step PCR
kit. First-strand cDNA synthesis was accomplished with the
primer skcc1b (Christopherson et al., 2000). PCR primers
and the fluorescent probe for real-time detection of ampli-
fied DNA that mapped to a highly conserved region in the
gag gene skcc1b (Christopherson et al., 2000) were de-
scribed previously (Fischer et al., 2003).
Phylogenic analyses of envelope fragments
RT-PCR, cloning, and sequencing of a HIV-1 env frag-
ment encompassing C2 and V3 were performed as described
previously (Fischer et al., 2004). Viral RNA was obtained
directly from plasma and patient PBMC and also from viral
isolates derived from plasma and PBMC cultures. Sixteen
clones per sample were analyzed. Sequences were manually
edited and aligned with Lasergene software version 5.06
(DNASTAR Inc., Madison, WI). Distances were calculated
by MEGA version 2.1 (S. Kumar et al.; http://www.
megasoftware.net) assuming a Tamura–Nei substitution
model. Phylogenetic trees were constructed for each patient
separately by maximum-likelihood method using T/T ratio
2.0, 10 replicate rounds of randomized sequence input, global
rearrangement option, and HXB2 as reference sequence
(PHYLIP version 3.6; J. Felsenstein, University of Washing-
ton, Seattle; http://evolution.genetics.washington.edu/
phylip.html). Trees were displayed with TreeView (version
1.6; R. Page, University of Glasgow, UK; http://taxonomy.
zoology.gla.ac.uk/rod/treeview.html). The clonal sequences
were grouped into distinct phylogenetic clusters if they were
separated by a branch having a length significantly different
from zero. Branch lengths were defined to be significantly
positive when zero was outside the confidence interval.
Sequences differing by less pronounced distances were
considered to belong to the same quasispecies.
Nucleotide sequence accession number
All C2-V3 env sequence described in Fig. 5 have been
deposited in Gene Bank under accession numbers
AY656249–AY656581.Acknowledgments
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